CCO Annual Update
HIV/AIDS Annual Update 2008
HIV Disease Pathogenesis and the Gastrointestinal Tract
|
Module 1 of 10
|
- Daniel Douek, MD, MRCP, PhD
|
|
|
 Daniel C. Douek, MD, MRCP, PhD, describes our current understanding of the relationship between loss of gut mucosal integrity in acute HIV-1 infection and disease progression through the chronic phase of infection and AIDS. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the pathologic changes to the gastrointestinal tract that are characteristic of HIV infection
- Discuss the effects of immune activation on the immune system of infected individuals
- Recount the effect of HAART on the gastrointestinal immune system
|
New Findings on Resistance to NRTIs, NNRTIs, and PIs
|
Module 3 of 10
|
|
|
|
Daniel R. Kuritzkes, MD, discusses the most recent data on resistance to NRTI, NNRTI, and PI antiretrovirals and resistance assays. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the clinical impact of HIV-1 drug resistance
- Review the prevalence of HIV-1 drug resistant mutations, as well as currently available detection assays
- Describe identified mutations that confer resistance to novel antiretroviral agents
|
Novel Antiretroviral Agents
|
Module 4 of 10
|
|
|
|
Joseph J. Eron, Jr., MD, discusses the efficacy, safety, and mechanisms of action of novel antiretroviral drug classes for the treatment of HIV. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms of action of newly approved agents from novel classes
- Recount the safety and efficacy of new agents from novel classes
- Summarize the safety and efficacy of the novel NNRTI etravirine
- Discuss the application of newly approved agents in clinical practice to improve rates of virologic suppression in treatment-experienced patients
|
Clinical Strategies for Initiation of Antiretroviral Therapy
|
Module 5 of 10
|
|
|
|
Joel E. Gallant, MD, MPH, discusses the latest strategies for the initiation of first-line antiretroviral therapy in HIV-infected patients. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the rationale for earlier vs later initiation of antiretroviral therapy
- Recount current treatment guidelines for first-line antiretroviral regimens
- Describe initial therapy modifications appropriate for special populations
- Explain data on newer agents in treatment-naive populations that may support future use of these agents for first-line therapy
|
Non−AIDS-Defining Cancers in the Era of HAART
|
Module 6 of 10
|
|
|
|
Alexandra M. Levine, MD, describes current treatment of lung cancer, HPV-based cancers, and Hodgkin’s lymphoma in HIV-infected patients. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the epidemiology and characteristics of lung cancer among HIV-infected patients
- Discuss the role of human papillomavirus in the etiology of anal and head and neck cancers
- Summarize the epidemiology, clinical characteristics, and treatment of Hodgkin’s disease among HIV-infected people
|
Neurologic Aspects of HIV Infection and Its Therapy
|
Module 7 of 10
|
- Justin C. McArthur, MBBS, MPH
|
|
|
Justin C. McArthur, MBBS, MPH, reviews the most recent findings in the neurologic manifestations of HIV infection and the related effects of antiretroviral therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize diagnostic criteria and clinical features of HIV-associated neurocognitive disease (HAND) in the HAART era
- Discuss changes in the incidence, prevalence, and progression of HAND before and after the introduction of HAART
- Describe a system for ranking individual ARVs and ARV combinations for their ability to penetrate the central nervous system
|
Advances in HIV/HCV Coinfection
|
Module 8 of 10
|
|
|
|
David L. Thomas, MD, MPH, discusses the latest data regarding treatment of patients with HIV/HCV-coinfection. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current findings on the natural history of acute and chronic HCV infection in HIV-infected people
- Describe predictors of obtaining a sustained virologic response in HIV/HCV-coinfected individuals
- Summarize the types of virologic responses a patient may experienced while on hepatitis C therapy and their importance for deciding on future treatment options
|
The US HIV Epidemic: Why Is Prevention Failing?
|
Module 9 of 10
|
|
|
|
Thomas J. Coates, PhD, reviews the current epidemiology of HIV infection in the United States and discusses the most recent developments in strategies to prevent HIV transmission. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the differential impacts of the HIV epidemic on US racial and geographic groups
- Discuss the advantages and disadvantages of current HIV prevention approaches
- Describe the current Centers for Disease Control and Prevention recommendations for HIV screening and testing
- Discuss the role of healthcare providers in HIV prevention efforts
|
The Global HIV Epidemic: Update on Epidemiology and Prevention
|
Module 10 of 10
|
|
|
|
Thomas C. Quinn, MD, MSc, reviews the most up-to-date data on the global epidemiology of HIV infection and transmission prevention efforts. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current trends in HIV epidemiology in major geographic regions of the world
- Identify current approaches to prevention of the sexual transmission of HIV infection
- Discuss key findings in the prevention of mother-to-child transmission of HIV infection
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|